Re-mobilization of hematopoietic progenitors for further autografting after prior myelo-ablative high-dose chemotherapy and autologous hematopoietic stem cell transplantation; the role of plerixafor

Leuk Lymphoma. 2019 Jul;60(7):1819-1822. doi: 10.1080/10428194.2018.1543879. Epub 2019 Jan 8.

Authors

Christos Kosmas¹, Eleftheria Kranidioti¹, Aikaterini Kosma¹, Maria Karakosta¹, Constantinos Miltiadous¹, Anastasios Grivas¹, Aggelos Athanasopoulos², Evangelos Lianos¹

Affiliations

¹ a Hematopoietic Cell Transplant Unit, Division of Medical Oncology, Department of Medicine , "Metaxa" Cancer Hospital , Piraeus , Greece.
² b Cryopreservation Laboratory , Blood Transfusion Service, "Metaxa" Cancer Hospital , Piraeus , Greece.

PMID: 30618317
DOI: 10.1080/10428194.2018.1543879

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Anti-HIV Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Autografts
Benzylamines
Combined Modality Therapy
Cyclams
Female
Follow-Up Studies
Hematologic Neoplasms / drug therapy
Hematologic Neoplasms / pathology
Hematologic Neoplasms / therapy*
Hematopoietic Stem Cell Mobilization / methods*
Hematopoietic Stem Cell Transplantation / methods*
Heterocyclic Compounds / therapeutic use*
Humans
Male
Middle Aged
Myeloablative Agonists / therapeutic use
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / pathology
Neoplasm Recurrence, Local / therapy*
Prognosis
Transplantation, Autologous
Young Adult

Substances

Anti-HIV Agents
Benzylamines
Cyclams
Heterocyclic Compounds
Myeloablative Agonists
plerixafor